Eugia Pharma Specialties receives USFDA approval for Bortezomib for Injection

4 May 2022 , 08:40 AM

Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialties, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bortezomib for injection, 3.5 mg. Bortezomib for Injection, 3.5 mg/vial (Single-Dose Vial) to be bioequivalent and therapeutically equivalent to the Velcade for Injection 3.5 mg/vial, of Takeda Pharmaceuticals U.S.A. Inc. The product is being launched immediately. The approved product has a market size of US$ 1172 million for the twelve months ending March 2022, according to IQVIA.

Bortezomib for injection is indicated for the treatment of
? Adult patients with multiple myeloma (cancer of plasma cells)
? Also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes)

Powered by Capital Market – Live News